CureVac NV
NASDAQ:CVAC

Watchlist Manager
CureVac NV Logo
CureVac NV
NASDAQ:CVAC
Watchlist
Price: 2.99 USD 1.01% Market Closed
Market Cap: 670.7m USD
Have any thoughts about
CureVac NV?
Write Note

Gross Margin
CureVac NV

70.9%
Current
-134%
Average
63.9%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
70.9%
=
Gross Profit
385.3m
/
Revenue
543.3m

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
DE
CureVac NV
NASDAQ:CVAC
670.8m USD
71%
FR
Pharnext SCA
OTC:PNEXF
6T USD
0%
US
Abbvie Inc
NYSE:ABBV
318.1B USD
67%
US
Amgen Inc
NASDAQ:AMGN
142.2B USD
60%
US
Gilead Sciences Inc
NASDAQ:GILD
117.1B USD
78%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.2B USD
86%
US
Epizyme Inc
F:EPE
94.1B EUR
76%
AU
CSL Ltd
ASX:CSL
135.7B AUD
52%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.7B USD
87%
US
Seagen Inc
F:SGT
39.3B EUR
75%
NL
argenx SE
XBRU:ARGX
36.2B EUR
89%
Country DE
Market Cap 670.8m USD
Gross Margin
71%
Country FR
Market Cap 6T USD
Gross Margin
0%
Country US
Market Cap 318.1B USD
Gross Margin
67%
Country US
Market Cap 142.2B USD
Gross Margin
60%
Country US
Market Cap 117.1B USD
Gross Margin
78%
Country US
Market Cap 105.2B USD
Gross Margin
86%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Country AU
Market Cap 135.7B AUD
Gross Margin
52%
Country US
Market Cap 78.7B USD
Gross Margin
87%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Country NL
Market Cap 36.2B EUR
Gross Margin
89%
No Stocks Found

CureVac NV
Glance View

Market Cap
670.8m USD
Industry
Biotechnology

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 500 full-time employees. The company went IPO on 2020-08-14. The firm is engaged in the therapeutic development of messenger Ribonucleic Acid (mRNA) and RNA-based vaccines. CureVac AG focuses on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases. The firm's pipeline focuses on three areas: cancer immunotherapy, prophylactic vaccines, and protein-based therapies.

CVAC Intrinsic Value
4.32 USD
Undervaluation 31%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
70.9%
=
Gross Profit
385.3m
/
Revenue
543.3m
What is the Gross Margin of CureVac NV?

Based on CureVac NV's most recent financial statements, the company has Gross Margin of 70.9%.